Dichloroacetate inhibits the degeneration of decellularized cardiovascular implants

Agunda Chekhoeva†, Sentaro Nakanishi†, Yukiharu Sugimura, Mahfuza Toshmatova, Anna Kathrin Assmann, Artur Lichtenberg, Payam Akhyari* and Alexander Assmann

Department of Cardiovascular Surgery and Research Group for Experimental Surgery, Heinrich Heine University, Medical Faculty, Duesseldorf, Germany

* Corresponding author. Department of Cardiac Surgery, Heinrich-Heine-University, Moorenstr.5, 40225 Duesseldorf, Germany. Tel: +49-211-81-18331; e-mail: payam.akhyari@med.uni-duesseldorf.de (P. Akhyari).

Received 25 November 2020; received in revised form 26 May 2021; accepted 11 June 2021

Abstract

OBJECTIVES: Intima hyperplasia is a major issue of biological cardiovascular grafts resulting in progressive in vivo degeneration that particularly decreases the durability of coronary and peripheral vascular bypasses. Previously, dichloroacetate (DCA) has been reported to prevent the formation of hyperplastic intima in injured arteries. In this study, the effect of DCA on the neointima formation and degeneration of decellularized small-caliber implants was investigated in a rat model.

METHODS: Donor rat aortic grafts (n = 22) were decellularized by a detergent-based technique, surface-coated with fibronectin (50 μl ml⁻¹, 24 h incubation) and implanted via anastomoses to the infrarenal aorta of the recipients. Rats in the DCA group (n = 12) received DCA via drinking water during the whole follow-up period (0.75 g l⁻¹), while rats without DCA treatment served as controls (n = 10). At 2 (n = 6 + 5) and 8 (n = 6 + 5) weeks, the grafts were explanted and examined by histology and immunofluorescence.

RESULTS: Systemic DCA treatment inhibited neointima hyperplasia, resulting in a significantly reduced intima-to-media ratio (median 0.78 [interquartile range, 0.51–1.27] vs 1.49 [0.67–2.39] without DCA, P < 0.001). At 8 weeks, neointima calcification, as assessed by an

†The first two authors contributed equally to this work.

© The Author(s) 2021. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
established von Kossa staining-based score, was significantly decreased in the DCA group (0 [0–0.25] vs 0.63 [0.06–1.44] without DCA, \( P < 0.001 \)). At 8 weeks, explanted grafts in both groups were luminally completely covered by an endothelial cell layer. In both groups, inflammatory cell markers (CD3, CD68) proved negative.

**CONCLUSIONS:** Systemic DCA treatment reduces adverse neointima hyperplasia in decellularized small-caliber arterial grafts, while allowing for rapid re-endothelialization. Furthermore, DCA inhibits calcification of the implants.

**Keywords:** Tissue engineering • Decellularization • Vascular graft • Intima hyperplasia • Graft degeneration • Dichloroacetate

**MATERIALS AND METHODS**

**Experimental design**

Male Wistar rats (\( n = 44 \), 22 donor rats, 22 recipient rats) weighing 200–250 g were obtained from the local animal care facility of the University Düsseldorf, Germany, and fed *ad libitum* with regular diet. All experiments were performed in agreement with the national animal welfare act and approved by the state animal care committee—reference number 84–02.04.2012.A391.

After explantation from donor animals, the aortic grafts were decellularized by means of a detergent-based protocol and coated with fibronectin. Thereafter, coated aortic grafts were implanted into the infrarenal aortas of the recipients. The recipient animals were distributed to 2 experimental groups: The DCA group (\( n = 12 \)) received engineered aortic grafts coated with fibronectin and systemic DCA therapy during the whole follow-up period (0.75 g l\(^{-1}\) via drinking water; ingested water monitored daily), while the control group (\( n = 10 \)) received only engineered aortic grafts coated with fibronectin and no systemic treatment. Animals in each group were observed for 2 and 8 weeks, respectively, resulting in \( n = 6 \) DCA rats and \( n = 5 \) control rats at each time point for implant readout. The sample size has been calculated estimating the effect size by Cohen’s \( d \) based on previous data on intima hyperplasia in fibronectin-coated decellularized grafts [4]. A schematic representation of the experiments including technical aspects is presented in Supplementary Material, Fig. S1, and a timeline of the experiments in Supplementary Material, Fig. S2.

All surgical procedures, the graft engineering as well as the readout methods were conducted according to standards previously established in our group [4, 10]. In the following, brief descriptions are provided.

**Surgical procedures**

**Donor operation.** Animals were euthanized by an overdose of isoflurane, after which a median sternotomy was performed followed by *en bloc* removal of the heart and the thoracic aorta. The aortic grafts were prepared containing the ascending aorta, aortic arch and descending aorta. After through preparation, the U-shaped aortic grafts were rinsed with heparinized phosphate-buffered saline (PBS).

**Graft decellularization.** The decellularization started with 4 cycles of 12 h with 0.5% sodium dodecyl sulphate + 0.5% deoxycholate + 0.05% sodium azide and with 2 cycles 2 h with DNase (2.3 mg ml\(^{-1}\) in PBS, followed by 4 repetitive 24 h washing cycles with PBS containing 1% penicillin/streptomycin (Sigma-Aldrich, Taufkirchen, Germany; Aldrich and Merck, Darmstadt, Germany). All steps were conducted in 15-ml tubes, filled with 12 ml, containing a maximum of 2 grafts.
**Graft coating.** All decellularized rat aortic prostheses intended for implantation (n = 22) were coated with fibronectin on both surfaces by incubation under the following conditions: fibronectin concentration 50 \( \mu \text{g ml}^{-1} \) in PBS (Sigma-Aldrich), incubation time 24 h and incubation temperature 37°C.

**Recipient operation.** The heterotopic implantation of the engineered aortic grafts was carried out according to a previously standardized approach [11], which is described in brief: Recipient rats were intubated, anaesthetized with 2.0–2.5% isoflurane, a central venous jugular vein catheter was inserted and carprofen was injected intraperitoneally. A midline laparotomy was performed, the intestines were mobilized and the aorta was dissected away from the vena cava at the level of the infrarenal aorta. After systemic administration of 300 IU kg\(^{-1}\) (body weight) heparin via the central venous catheter and aortic clamping within this segment, 2 incisions were made to create distal and proximal openings for the anastomoses. The anastomoses were sutured in an end-to-side manner, with a continuous 10–0 suture (Ethicon, Norderstedt, Germany). Following release of blood flow through the graft, the native aorta between the 2 anastomoses was ligated to improve perfusion of the implant. After clinical observation, particularly paying attention to the perfusion of the lower extremities, the abdomen was closed, and after sonographic confirmation of unimpaired graft perfusion with a Philips HDX 11 ultrasonography system equipped with a 15-MHz probe (Philips, Amsterdam, Netherlands), the recipients were allowed to recover from anaesthesia.

**Graft explantation.** Two or 8 weeks after implantation, the recipient rats were anaesthetized and Doppler sonography was conducted to control the perfusion of the prostheses. After median laparotomy, the aortic grafts were excised and further processed for histology and immunohistology.

**Morphological characterization of explanted grafts**

**Histology.** Cryo-sections (5-\( \mu \text{m} \) thick) were generated for histological staining. For characterization of the vascular wall and cell layers, haematoxylin/eosin staining was used. Von Kossa staining was applied to determine the degree of calcification. Movat pentachrome staining was chosen for the detection of matrix components.

Comparative quantification of the luminal neo-intima formation and graft calcification was performed by standardized scoring as previously published [12] (Supplementary Material).

**Immunohistology.** Cryo-sections were incubated for 10 min with 4% formalin, for 10 min with 0.25% Triton-X-100 (Sigma-Aldrich) and for 1 h with 5% bovine serum albumin (Sigma-Aldrich) at room temperature.

Smooth muscle cells were visualized with the anti-alpha smooth muscle actin (\( \alpha \text{SMA}, \text{Sigma-Aldrich} \)). Endothelial cells were detected using anti-von Willebrand factor (VWF, Dako, Hamburg, Germany). For inflammatory processes, anti-CD3 (Sigma-Aldrich) for T cells and anti-CD68 (Abcam, Cambridge, UK) for macrophages were evaluated. Thereafter, the sections were washed 3 times in PBS containing 0.1% Tween-20. As secondary antibodies, Alexa 546 and Alexa 488 (Invitrogen, Carlsbad, USA) + 1% bovine serum albumin were applied for 45 min at 37°C. Control sections were incubated with PBS without primary antibodies. After 1 h incubation, sections were washed again 3 times in PBS. Sections were covered with Vectashield antifade mounting medium with 4',6-diamidino-2-phenylindole (Vector Labs, Peterborough, UK) and image acquisition was performed with a microscope system DM 2000, equipped with a digital Application Suite V3.7 software.

**Statistical analysis**

Data are presented as median and interquartile range (IQR) for all continuous variables. Following normality assessment (D’Agostino-Pearson test), direct group comparisons were conducted by two-tailed Mann-Whitney U tests or two-tailed Student’s t-tests, respectively. Statistical significance was considered if \( P \)-values were lower than 0.05. Data analysis was conducted using Graph Pad Prism v6.01 (Graph Pad Software, San Diego, USA).

**RESULTS**

**Operative results**

All 22 decellularized aortic grafts, coated with fibronectin, were successfully implanted and remained functional for up to 2 and 8 weeks, after which they were explanted. All animals showed normal clinical function during the follow-up and recovered from surgery without signs of neurological or ischaemic symptoms of the lower limbs.

**Cellular graft repopulation**

Histology of the explants revealed a progressive luminal re-endothelialization within 8 weeks after transplantation, with significantly increased luminal coverage compared to the data at 2 weeks \( (P < 0.001) \), however, without a statistically significant inter-group difference regarding treatment (Fig. 1). After 8 weeks,

![Figure 1: Semiquantitative analysis of the luminal recellularization with neointima in the control and dichloroacetate group after 2 and 8 weeks in vivo. In all 4 regions, the aortic grafts were completely covered with neointima after 8 weeks in both groups without significant intergroup differences. The upper and lower borders of the boxes represent the upper and lower quartiles. The middle horizontal line represents the median. The upper and lower whiskers represent the maximum and minimum values.](image-url)
neointima coverage was complete throughout the length of the grafts in both groups (Supplementary Material, Fig. S3).

After 2 weeks, the neointima in the control group presented with hyperplastic areas, while the DCA group showed predominantly single-layer endothelium. By week 8, intima hyperplasia had progressed in both groups, however, to a larger extent in group control. By Movat’s pentachrome staining, hyperplastic intima in the control group showed higher collagen content and generally more intercellular substance (Fig. 2).

To quantify the extent of hyperplastic neointima formation, the intima-to-media ratio was calculated (Fig. 3). After 2 weeks, the intima-to-media ratio in group DCA was significantly decreased at the level of the distal anastomosis (region B2) (0.55 [IQR, 0.34–1.60] vs 0.65 [IQR, 0.40–2.76] in group control; \( P = 0.043 \)). After 8 weeks, overall hyperplastic intima formation was significantly decreased in the DCA group as compared to the control group (0.78 [IQR, 0.51–1.27] vs 1.49 [IQR, 0.67–2.39], \( P < 0.001 \)). In 3 of the 4 regions of the implants, there was a significantly lower intima-to-media ratio at 8 weeks (region A1: 1.23 [IQR, 0.97–1.47] vs 1.73 [IQR, 0.90–2.54], \( P = 0.0225 \); region A2: 0.65 [IQR, 0.52–1.08] vs 1.48 [IQR, 1.28–2.39], \( P = 0.001 \); region B1: 0.96 [IQR, 0.51–1.39] vs 1.93 [IQR, 0.93–3.11], \( P = 0.024 \); region B2: 0.61 [IQR, 0.38–0.74] vs 0.99 [IQR, 0.33–1.30], \( P = 0.057 \)).

Immunofluorescence analysis of the cell populations participating in the development of neointima of the vessel grafts revealed a vWF-positive monolayer of endothelial cells at the luminal surfaces of the grafts, and multi-layered intima regions stained positive for αSMA (Fig. 4). Inflammatory cell markers were not relevantly positive in any group at any time point (Supplementary Material, Fig. S4).
Graft degeneration

To visualize graft calcification processes, von Kossa staining was performed (Supplementary Material, Fig. S6). The amount of hydroxyapatite deposition in the neointima after 8 weeks was significantly lower in the DCA group than in the control group (region A1: 0 [IQR, 0–0] vs 0 [IQR, 0–1], P = 0.030; region A2: 0 [IQR, 0–0] vs 0 [IQR, 0–0], P = 0.015; region B1: 0 [IQR, 0–0.75] vs 1 [IQR, 0–2], P = 0.008; region B2: 0 [IQR, 0–0] vs 1 [IQR, 0–1], P = 0.003) (Fig. 7A). The difference in calcium burden in the media showed statistical significance in the perianastomotic regions at 8 weeks, with decreased calcification in the DCA group (region A1: 0 [IQR, 0–0] vs 0 [IQR, 0–0], P = 0.008; region B2: 0 [IQR, 0–0] vs 1 [IQR, 0–1], P = 0.047) (Fig. 7B).

DISCUSSION

Graft decellularization techniques aim at effective cell removal while preserving the extracellular matrix structure. The most commonly used decellularization techniques include methods of chemical, enzymatic and mechanical treatment [1]. The resulting decellularized scaffolds are prone to cause thrombosis, intima hyperplasia or aneurysms due to the absence of a closed endothelial layer [13]. Bioactive surface coating prior to graft transplantation can be used to accelerate the autologous in vivo recellularization, thereby counteracting the above mentioned adverse effects.

In the current study, we have used fibronectin coating since we had previously shown that fibronectin induces accelerated medial graft repopulation in the absence of an inflammatory reaction [4]. Unfortunately, fibronectin in our previous study had not only accelerated neointima formation, but also aggravated intima hyperplasia, so that a different strategy was necessary to overcome this issue. To inhibit neointimal hyperplasia, systemic DCA treatment was administered, and the effect was analysed 2 and 8 weeks after graft implantation.

DCA is a small molecule, a structural analogue of pyruvate, that is commonly used to inhibit pyruvate dehydrogenase kinases (PDK), reduce cellular proliferation and induce apoptosis [14]. DCA activates the pyruvate dehydrogenase complex by inhibition of the PDK isomerase 2. Pharmacologic PDK2 blockade with DCA prevents hyperpolarization of the mitochondrial membrane potential, thereby inducing apoptosis and thus reducing hyperplastic neointima formation in injured vessels [15].

In numerous studies, DCA has shown protective effects on myocardial ischaemia [16], cancer [14], pulmonary hypertension [8], platelet aggregation and arterial thrombosis without altering hemostasis [17]. It was also reported that neointima formation in native human arteries is driven by hyperpolarization of the mitochondrial membrane potentials in vascular smooth muscle cells, which can be counteracted by DCA treatment [9].

While synthetic vascular prostheses offer good long-term patency for the replacement of large arteries with high blood flow, such as the aorta, synthetic grafts with small diameters (<6 mm), such as in coronary or peripheral vascular surgery, show poor patency rates [18, 19]. Similarly, small-caliber allogenic and xenogenic grafts, independently of their usage in a fresh or a cryopreserved state, have proven not to be adequate substitutes for available autologous bypass vessels, such as saphenous veins or internal thoracic arteries or radial arteries [18, 20]. For synthetic as well as biological small-caliber grafts, thrombogenicity due to the lack of autologous endothelium and progressive intima hyperplasia resulting in calcifying degeneration are the driving forces of graft failure. In this context, we envision that the inhibition of intima hyperplasia and subsequent calcification in tissue-engineered...
small-caliber arterial grafts by DCA treatment, while allowing for rapid autologous endothelium formation in vivo, can contribute to an improvement in long-term patency of biological implants for arterial replacement or bypass surgery, respectively.

The results of our study show that short-term intake of DCA via drinking water significantly inhibits intima hyperplasia in decellularized small-caliber arterial grafts and does not impair implant re-endothelialization, resulting in complete neoendothelium coverage within 8 weeks in vivo. The perianastomotic regions of the grafts were re-endothelialized earlier than the aortic arches, supporting the hypothesis of graft repopulation predominantly via cellular ingrowth from the anastomotic regions, which is in line with previous results from studies on the in vivo fate of decellularized aortic grafts [11, 21]. Not only the rapid luminal endothelialization with vWF-positive cells, but also the migration of αSMA-positive interstitial cells from the adventitial side into the graft media confirm those data from our small animal implant model [4]. Here, we had shown that the migration of adventitial αSMA-positive cells into the media is mediated by fibronectin coating. Furthermore, the observation that media recellularization is emphasized in the perianastomotic regions suggests that ingrowth from the host tissue around the anastomoses, presumably by αSMA-positive activated fibroblasts, plays a role also for the media.

Regarding the pattern of intima hyperplasia in the grafts, the distal preanastomotic region (B2) was less affected after 8 weeks. This finding may be attributed to haemodynamic forces in the implants, particularly to wall shear stress. Low local shear stress and oscillatory shear stress have been reported to favor intima hyperplasia and accelerate atherosclerotic plaque growth [22, 23]. Due to the end-to-side manner of the anastomoses and the mismatch in diameters of the graft and the native aorta, the direction of blood flow changes substantially when entering the graft, and flow disturbances clearly occur in the proximal parts of the implant. This presumably results in heterogeneous wall shear stress patterns with crucial local differences, favoring intima hyperplasia. In the distal preanastomotic part of the graft, which is located at the end of the long graft arch, the blood flow may have restructured to a laminar flow, potentially explaining the lower degree of intima hyperplasia in this area. In order to test this hypothesis, blood flow analyses by computational fluid dynamics should be conducted.

That DCA therapy in animals with implanted decellularized arterial grafts decreases neointima hyperplasia in our study, is in agreement with a previous study on DCA treatment that counteracted intima hyperplasia in injured native vessels [9]. Beyond inhibition of hyperplasia, the present study revealed a significant inhibitory effect of DCA on the degenerative calcification in the neointima within only 8 weeks after graft implantation, and inhibition of media calcification particularly in the perianastomotic regions. As we have previously shown for grafts that are recellularized in vivo, calcification of the neointima in the present experiments occurred predominantly in areas of hyperplastic intima formation [10, 12]. Therefore, the observed hyperplasia reduction by DCA seems to be causal for the inhibition of implant calcification. According to previous studies on vascular and valvular grafts decellularized with our detergent-based protocol, implantation of the prostheses in the present study did not result in detectable inflammatory response, indicating effective donor cell removal during the decellularization process [4, 11].
Another limitation in our data is that a single concentration of administered DCA has been researched on. Although 0.75 g l⁻¹ drinking water is an established concentration in rat models, and the weight-normalized calculation (69.9 [IQR, 68.5–74.2] mg kg⁻¹ (body weight) day⁻¹) is in the range that has been administered in human trials [8], it may be interesting to examine whether substantially lower DCA concentrations cause similar anti-degenerative effects. In addition, it has to be tested if a short-term intake of DCA over a few weeks after implantation suffices, or if long-term therapy is required to avoid graft degeneration. In this context, addressing controversially discussed potential toxicity of DCA, evaluation of halogen-substituted DCA analogues that have been reported to exhibit lower toxicity in the presence of high binding affinity would be another future research project [30].

Finally, it may sound controversial to treat acellular implants with a substance that affects mitochondria. However, implant deterioration is predominantly driven by invading autologous cells that induce pro-degenerative cascades, and therefore, preventive measures during the repopulation process can effectively inhibit graft degeneration, such as DCA in the present study.

CONCLUSION

The present study demonstrates that systemic DCA therapy decreases adverse neointima hyperplasia in decellularized small-caliber arterial grafts, while allowing for rapid re-endothelialization of the implants in a standardized rat model. Furthermore, to the best of our knowledge, we revealed for the first time that DCA may have a role in anti-calcification of tissue-engineered biological prostheses.

SUPPLEMENTARY MATERIAL

Supplementary material is available at EJCTS online.

Funding

The study was supported by institutional funds of the Department of Cardiovascular Surgery.

Conflicts of interest: none declared.

Author contributions

Agunda Chekhoeva: Data curation; Writing—original draft. Sentaro Nakanishi: Data curation; Formal analysis. Yukiharu Sugimura: Data curation; Formal analysis; Methodology. Mahfuza Toshmatova: Data curation; Formal analysis. Anna Kathrin Assmann: Data curation; Formal analysis. Artur Lichtenberg: Funding acquisition; Resources; Supervision; Writing—review & editing. Payam Akhyari: Conceptualization; Project administration; Resources; Supervision; Writing—review & editing. Alexander Assmann: Conceptualization; Project administration; Supervision; Writing—review & editing.

Reviewer information

European Journal of Cardio-Thoracic Surgery thanks Stephen R. Large, Ari Mennander and the other, anonymous reviewer(s) for their contribution to the peer review process of this article.
References

[1] Moroni F, Mirabella T. Decellularized matrices for cardiovascular tissue engineering. Am J Stem Cells 2014;3:1–20.
[2] Sayk F, Bos I, Schubert U, Wedel T, Sievers HH. Histopathologic findings in a novel decellularized pulmonary homograft: an autopsy study. Ann Thorac Surg 2005;79:1755–8.
[3] Flameng W, De Visscher G, Mesure L, Hermans H, Jashari R, Meuris B. Coating with fibronectin and stromal cell-derived factor-1alpha of decellularized homografts used for right ventricular outflow tract reconstruction eliminates immune response-related degeneration. J Thorac Cardiovasc Surg 2014;147:1398–404.e2.
[4] Assmann A, Delfs C, Munakata H, Schiffer F, Horstkotter K, Huynh K et al. Acceleration of autologous in vivo recellularization of decellularized aortic conduits by fibronectin surface coating. Biomaterials 2013;34: 6015–26.
[5] Mizuno Y, Iwata H, Takagi H, Yoshikawa S, Umeda Y, Matsuno Y et al. Sonoporation with doxorubicin enhances suppression of intimal hyperplasia in a vein graft model. J Surg Res 2005;124:312–7.
[6] Bennett MR, Anglin S, McEwan JR, Jagoe R, Newby AC, Evan GI. Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides. J Clin Invest 1994;93: 820–8.
[7] Lindner V, Reidy MA. Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc Natl Acad Sci USA 1991;88:3739–43.
[8] McMurtry MS, Bonnet S, Wu X, Dyck JR, Haromy A, Hashimoto K et al. Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ Res 2004;95:830–40.
[9] Deuse T, Hua X, Wang D, Maegdefessel L, Heeren J, Scheja L et al. Dichloroacetate prevents restenosis in preclinical animal models of vessel injury. Nature 2014;509:641–4.
[10] Assmann A, Zwirnmann K, Heidelberg F, Schiffer F, Horstkotter K, Munakata H et al. The degeneration of biological cardiovascular prostheses under pro-calcific metabolic conditions in a small animal model. Biomaterials 2014;35:7416–28.
[11] Assmann A, Akhyari P, Delfs C, Flogel U, Jacoby C, Kamiya H et al. Development of a growing rat model for the in vivo assessment of engineered aortic conduits. J Surg Res 2012;176:367–75.
[12] Assmann A, Horstkotter K, Munakata H, Schiffer F, Delfs C, Zwirnmann K et al. Simvastatin does not diminish the in vivo degeneration of decellularized aortic conduits. J Cardiovasc Pharmacol 2016;64:332–42.
[13] Simsa R, Padma AM, Heeren J, Scheja L, Altmann K et al. Systematic in vitro comparison of decellularization protocols for blood vessels. PLoS One 2018;13:e0209269.
[14] Woollbright BL, Choudhary D, Mikhailik A, Trammel C, Shanmugam S, Abbott E et al. The role of pyruvate dehydrogenase kinase-4 (PDHk4) in bladder cancer and chemoresistance. Mol Cancer Ther 2018;17:2004–12.
[15] Deuse T, Hua X, Wang D, Maegdefessel L, Heeren J, Scheja L et al. Dichloroacetate prevents restenosis in preclinical animal models of vessel injury. Nature 2014;509:641–4.
[16] Walters AM, Porter GA, Jr., Brookes PS. Mitochondria as a drug target in ischemic heart disease and cardiomyopathy. Circ Res 2012;111:1222–36.
[17] Naya MK, Dhanesha N, Dodapattar P, Rodriguez O, Sonkar VK, Dayal S et al. Dichloroacetate, an inhibitor of pyruvate dehydrogenase kinases, inhibits platelet aggregation and arterial thrombosis. Blood Adv 2018;2:2029–38.
[18] Desai M, Seifalian AM, Hamilton G. Role of prosthetic conduits in coronary artery bypass grafting. Eur J Cardiothorac Surg 2011;40:394–8.
[19] Klinkert P, Post PN, Breslau PJ, van Bockel JH. Saphenous vein versus PTFE for above-knee femoropopliteal bypass. A review of the literature. Eur J Vasc Endovasc Surg 2004;27:357–62.
[20] Farber A, Major K, Wagner WH, Cohen JL, Cosman DV, Lateurbach SR et al. Cryopreserved saphenous vein allografts in infragenual revascularization: analysis of 240 grafts. J Vasc Surg 2003;38:15–21.
[21] Assmann A, Struiß M, Schiffer F, Heidelberg F, Munakata H, Timchenko EV et al. Improvement of the in vivo cellular repopulation of decellularized cardiovascular tissues by a detergent-free, non-proteolytic, actin-disassembling regimen. J Tissue Eng Regen Med 2017;11:3530–43.
[22] Koskinas KC, Chatzizisis YS, Antoniadis AP, Giannoglou GD. Role of endothelial shear stress in stent restenosis and thrombosis: pathophysiological mechanisms and implications for clinical translation. J Am Coll Cardiol 2012;59:1337–49.
[23] Haruguchi H, Teraoka S. Intimal hyperplasia and hemodynamic factors in arterial bypass and arteriovenous grafts: a review. J Artif Organs 2003;6:227–35.
[24] Rieder E, Seebacher G, Kasimir MT, Eichmair E, Winter B, Dekan B et al. Tissue engineering of heart valves: decellularized porcine and human valve scaffolds differ importantly in residual potential to attract mononuclear cells. Circulation 2005;111:2792–7.
[25] Perrotta I, Russo E, Camasta C, Filice G, Di Mizio G, Colosimo F et al. New evidence for a critical role of elastic in calcification of native heart valves: immunohistochemical and ultrastructural study with literature review. Histopathology 2011;59:504–13.
[26] Tataranni T, Piccoli C. Dichloroacetate (DCA) and cancer: an overview towards clinical applications. Oxid Med Cell Longev 2019;2019:8201079.
[27] Stacpoole PW, Henderson GN, Yan Z, Cornett R, James MO. Pharmacokinetics, metabolism and toxicology of dichloroacetate. Drug Metab Rev 1998;30:499–539.
[28] Bersin RM, Wolfe C, Kwasman M, Lau D, Klinski C, Tanaka K et al. Improved hemodynamic function and mechanical efficiency in congestive heart failure with sodium dichloroacetate. J Am Coll Cardiol 1994;23:1617–24.
[29] Sugimura Y, Schmidt AK, Lichtenberg A, Assmann A, Akhyari P. A rat model for the in vivo assessment of biological and tissue-engineered valvular and vascular grafts. Tissue Eng C: Methods 2017;23:982–94.
[30] Subramanian K, Ramaia AS. Development of a less toxic dichloroacetate analogue by docking and descriptor analysis. Bioinformation 2010;5:73–6.